Global Urinary Tract Cancer Market Size study & Forecast, by Cancer Type (Bladder Cancer, Urethral cancer and Ureteric and Renal Pelvic Cancer), Treatment Type (Chemotherapy, and Immunotherapy), and Distribution Channel (Retail Pharmacy, and Online Pharma

Global Urinary Tract Cancer Market Size study & Forecast, by Cancer Type (Bladder Cancer, Urethral cancer and Ureteric and Renal Pelvic Cancer), Treatment Type (Chemotherapy, and Immunotherapy), and Distribution Channel (Retail Pharmacy, and Online Pharmacy) and Regional Analysis, 2022-2029

Global Urinary Tract Cancer Market is valued approximately USD 2.02 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 18.6% over the forecast period 2022-2029. Urinary Tract Cancer is a type of cancer that affects urethra, bladder, and renal pelvic. Urethral cancer affects the tube that carries urine from bladder to outside of the body. Whereas in Bladder Cancer the healthy cells in the bladder lining called as urothelial cells, change, and grow out of control and form a tumor. Chemotherapy, and Immunotherapy are used as treatment procedure for treatment of Urinary Tract Cancer. The increasing prevalence of bladder cancer and growing number of funding activities from private & government organizations as well as strategic initiatives from leading market players are key factors accelerating the market growth.

According to the World Cancer Research Fund International – in 2020, around 573278 new cases of bladder cancer were reported worldwide, representing 3.2% of all cancer type. Moreover, as per American Cancer Society’s estimates – in 2022, around 81,180 new cases of bladder cancer (about 61,700 in men and 19,480 in women) reported across the United States. In addition, around 17,100 individuals lost their lives due to bladder Cancer. Also, surge in sedentary lifestyle and rising healthcare infrastructure in emerging regions would create lucrative growth prospectus for the market over the forecast period. However, the high treatment cost associated with Urinary tract cancer and side effects associated with prescribed drugs impede the market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Urinary Tract Cancer Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share due to factors such as Increasing incidences of bladder cancer as well as availability of robust healthcare infrastructure in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising number of geriatric individuals as well as increasing penetration of super specialty hospitals and cancer care centers in the region.

Major market player included in this report are:
Astellas Pharma Inc.
Bristol-Myers Squibb Company
Eli Lily and Company
Endo International plc.
Exelixis, Inc.
GlaxoSmithKline Plc. (GSK)
Merck KGAA
Novartis AG
Pfizer Inc.
Johnson & Johnson

Recent Developments in the Market:
In April 2019, Janssen Pharmaceutical received the US Food and Drug Administration (FDA) approval for the drug Balversa (erdafitinib). This new drug is intended for treatment of metastatic urothelial carcinoma (mUC), a type of bladder cancer.

In September 2021, MSN Labs launched Cabolong, a branded generic of Cabozantinib, for the treatment of renal cancer. This new drug would be available in 20mg/40mg/60mg formulation.

Global Urinary Tract Cancer Market Report Scope:
Historical DataCompanies Mentioned

Astellas Pharma Inc.
Bristol-Myers Squibb Company
Eli Lily and Company
Endo International plc.
Exelixis, Inc.
GlaxoSmithKline Plc. (GSK)
Merck KGAA
Novartis AG
Pfizer Inc.
Johnson & Johnson

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.